Vertical sleeve gastrectomy vs gastric bypass are the two most commonly performed bariatric surgical procedures in the UK, yet they differ significantly in technique, metabolic effects, risks, and long-term requirements. Choosing between them is rarely straightforward and depends on individual health factors, comorbidities, and personal circumstances. This article compares both procedures across key areas — including how they work, NHS eligibility criteria, weight loss and health outcomes, risks, recovery, and how to make an informed decision alongside your bariatric multidisciplinary team.

How Vertical Sleeve Gastrectomy and Gastric Bypass Work

Sleeve gastrectomy removes 75–80% of the stomach to restrict intake and reduce ghrelin, while gastric bypass creates a small pouch and reroutes the bowel, producing both restrictive and significant hormonal metabolic effects.

Both vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB) are established bariatric surgical procedures designed to achieve significant, sustained weight loss. Understanding how each works mechanically and metabolically is essential when weighing up the options.

Vertical sleeve gastrectomy involves the permanent removal of approximately 75–80% of the stomach, leaving a narrow, sleeve-shaped tube roughly the size of a banana. This dramatically reduces stomach capacity, limiting food intake. VSG also removes the fundus of the stomach — the region responsible for producing ghrelin, a hormone that stimulates hunger. Beyond this, VSG produces favourable hormonal changes, including increased secretion of GLP-1 and PYY, which further reduce appetite and improve blood glucose regulation.

Gastric bypass is a more complex, two-stage procedure. First, a small gastric pouch (approximately 15–30 ml) is created from the upper stomach. The small intestine is then divided and rerouted so that food bypasses the majority of the stomach and the first section of the small intestine (the duodenum and part of the jejunum). This creates both a restrictive effect (smaller stomach pouch) and a malabsorptive effect. It is important to note that in standard proximal RYGB, macronutrient malabsorption is modest; however, the procedure significantly increases the risk of micronutrient deficiencies. RYGB also produces pronounced hormonal changes — including markedly increased GLP-1 and PYY secretion — that improve insulin sensitivity and satiety signalling.

Both procedures are performed laparoscopically (keyhole surgery) in most NHS and private centres, reducing recovery time and surgical risk compared with open approaches. Gastric bypass is generally considered the more technically demanding of the two, which has implications for surgical risk and the expertise required from the operating team. Further information on how each procedure works is available on the NHS website and through the British Obesity and Metabolic Surgery Society (BOMSS) patient information resources.

Eligibility Criteria and NHS Referral Pathways

NHS eligibility follows NICE CG189, requiring a BMI of 40 kg/m² or above (or 35–39.9 kg/m² with a significant comorbidity), with referral through Tier 3 specialist weight management services before Tier 4 surgical assessment.

Access to bariatric surgery on the NHS is governed by guidance from the National Institute for Health and Care Excellence (NICE) (CG189, Obesity: identification, assessment and management) and the NHS England Clinical Commissioning Policy for Complex and Specialised Obesity Surgery (Adults). Eligibility is based on clinical criteria rather than cosmetic considerations, and referral typically follows a structured pathway through specialist weight management services.

According to NICE CG189, bariatric surgery should be considered for adults who meet all of the following criteria:

• A BMI of 40 kg/m² or above, or a BMI of 35–39.9 kg/m² with a significant obesity-related comorbidity (such as type 2 diabetes, hypertension, or obstructive sleep apnoea)

• Completion of, or active engagement with, a structured weight management programme

• Fitness for anaesthesia and surgery

• Commitment to long-term follow-up

NICE also recommends that bariatric surgery be considered for adults with recent-onset type 2 diabetes at a BMI of 30–34.9 kg/m², recognising the strong metabolic benefit in this group. For people of South Asian or other Asian family origin, these thresholds are adjusted downward (typically by 2.5 kg/m²) to reflect increased metabolic risk at lower body weights — for example, surgery may be considered at a BMI of 27.5–32.4 kg/m² in the context of recent-onset type 2 diabetes. These lower thresholds apply in defined clinical contexts and are not a blanket criterion for all individuals from these backgrounds.

Referral is usually initiated by a GP and directed to a Tier 3 specialist weight management service, where a multidisciplinary team (MDT) — including dietitians, psychologists, physicians, and surgeons — assesses suitability. Those who meet surgical criteria are then referred on to Tier 4 specialist surgical services. Psychological evaluation is a key component, as bariatric surgery requires significant behavioural change. Patients with untreated eating disorders or uncontrolled mental health conditions may need additional support before surgery is considered. Waiting times on the NHS can be lengthy, and some patients opt for treatment through private providers, though the same clinical eligibility principles generally apply.

Comparing Weight Loss Outcomes and Health Benefits

Gastric bypass typically achieves greater total body weight loss (25–35%) and higher type 2 diabetes remission rates than sleeve gastrectomy, though both procedures significantly improve metabolic health and reduce all-cause mortality.

Both procedures deliver clinically meaningful weight loss, but the evidence suggests differences in magnitude and durability that are relevant to individual decision-making.

Gastric bypass is generally associated with greater total weight loss. Evidence from systematic reviews and long-term cohort studies — including the Swedish Obese Subjects (SOS) study and Cochrane reviews comparing RYGB with VSG — indicates that RYGB typically produces a total body weight loss (TBWL) of approximately 25–35% at one to five years, compared with approximately 20–30% for VSG. These figures are sometimes expressed as excess weight loss (EWL) — the proportion of weight above a healthy BMI that is lost — with RYGB achieving roughly 60–80% EWL and VSG approximately 50–70% EWL at five years. Individual outcomes vary considerably depending on adherence to dietary and lifestyle changes, pre-operative weight, and comorbidity profile.

In terms of metabolic benefits, gastric bypass has a particularly strong evidence base for the remission of type 2 diabetes, with remission rates of approximately 60–80% reported in the literature, sometimes occurring within days of surgery before significant weight loss has taken place. This is attributed to the profound hormonal changes following intestinal rerouting, including markedly increased GLP-1 secretion. It is important to note that definitions of remission vary across studies, and remission rates may decline over time. VSG also achieves meaningful diabetes remission (approximately 50–60%), though typically to a lesser degree. These figures should be discussed with the surgical team in the context of individual health profiles.

Both procedures are associated with improvements in:

• Hypertension and cardiovascular risk factors

• Obstructive sleep apnoea

• Non-alcoholic fatty liver disease (NAFLD), also increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD)

• Joint pain and mobility

• Mental health and quality of life

Long-term data from the SOS study and other established cohorts support the conclusion that bariatric surgery reduces all-cause mortality compared with non-surgical management of severe obesity. The choice between procedures should therefore consider not just weight loss targets but the individual's metabolic health priorities.

Risks, Complications, and Long-Term Considerations

Gastric bypass carries additional risks including internal hernia, marginal ulcers, dumping syndrome, and greater micronutrient deficiency; sleeve gastrectomy may worsen pre-existing gastro-oesophageal reflux disease.

As with any major surgical procedure, both VSG and gastric bypass carry risks. These should be discussed thoroughly with the surgical team as part of the informed consent process.

Short-term surgical risks common to both procedures include:

• Bleeding, infection, and anaesthetic complications

• Venous thromboembolism (VTE), mitigated by prophylactic anticoagulation and early mobilisation

• Staple-line or anastomotic leaks — a serious risk with both procedures (occurring at the staple line in VSG and at the anastomosis in RYGB); comparative rates differ by site and technique

• Conversion to open surgery if a laparoscopic approach is not feasible

Longer-term complications differ between the two procedures. VSG carries a risk of gastro-oesophageal reflux disease (GORD), which may worsen post-operatively; patients with pre-existing GORD may be better suited to bypass. Gastric bypass carries additional specific risks including:

• Internal hernia — a potentially serious complication arising from the rerouted bowel, which may present with intermittent or severe abdominal pain

• Marginal ulcers at the gastrojejunal anastomosis — risk is increased by smoking and NSAID use; patients are typically advised to avoid NSAIDs and smoking after bypass, and many centres prescribe a proton pump inhibitor (PPI) routinely

• Anastomotic strictures

• Post-prandial hypoglycaemia (late dumping syndrome) — low blood glucose occurring one to three hours after eating, distinct from early dumping

• Cholelithiasis (gallstones) — rapid weight loss increases gallstone risk after both procedures; ursodeoxycholic acid prophylaxis may be prescribed in the early post-operative period

Due to its malabsorptive component, gastric bypass carries a higher risk of nutritional deficiencies, particularly in:

• Iron (especially in premenopausal women)

• Vitamin B12

• Calcium and vitamin D

• Folate

In line with BOMSS guidelines and NHS guidance, lifelong vitamin and mineral supplementation and regular blood monitoring are required after both RYGB and VSG — not only after bypass. Patients must not discontinue supplements without medical guidance. Gastric bypass also carries a risk of early dumping syndrome — a rapid gastric emptying response to sugary or high-fat foods causing nausea, flushing, and palpitations — which is often manageable through dietary adjustment.

Weight regain over time is possible with both procedures, particularly if lifestyle changes are not maintained, and revision surgery may occasionally be required.

If you experience any unexpected symptoms after surgery — including those related to medicines or medical devices used during your care — you can report these via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Recovery, Lifestyle Changes, and Aftercare Support

Most patients are discharged within one to three days and return to light activities within two to four weeks; lifelong dietary changes, supplementation, and structured follow-up are essential for both procedures.

Recovery from bariatric surgery requires careful planning and a genuine commitment to long-term lifestyle modification. Surgery is a tool, not a cure, and outcomes are strongly influenced by post-operative behaviour.

Immediately following surgery, patients typically remain in hospital for one to three days. A staged dietary progression is followed, moving from fluids through to pureed and then soft foods before reintroducing solid foods. The exact timeline varies between centres and individual patients; your bariatric MDT will provide a personalised dietary plan and you should follow your local team's protocol rather than a fixed schedule.

Most patients can return to light activities within two to four weeks and resume desk-based work within a similar timeframe, though physically demanding roles may require six weeks or more. Driving is usually restricted for two to four weeks post-operatively.

Long-term lifestyle changes are essential and include:

• Eating small, regular meals and chewing thoroughly

• Avoiding high-sugar and high-fat foods (particularly important after bypass to reduce dumping symptoms)

• Separating fluids from meals to avoid discomfort

• Avoiding NSAIDs (such as ibuprofen) and smoking, particularly after gastric bypass

• Minimising alcohol — absorption is enhanced after RYGB, increasing the risk of intoxication and alcohol-related harm

• Engaging in regular physical activity, building gradually towards at least 150 minutes of moderate-intensity exercise per week, in line with UK Chief Medical Officers' physical activity guidelines

• Attending all follow-up appointments and blood tests

Structured follow-up is a key part of aftercare. In line with BOMSS recommendations, reviews typically occur at three, six, and twelve months post-operatively, then annually. Blood monitoring usually includes full blood count, ferritin, vitamin B12, folate, calcium, vitamin D, PTH, liver function tests, and urea and electrolytes, with trace elements checked as clinically indicated. Your GP will be involved in ongoing monitoring alongside the bariatric team.

Contraception and pregnancy: Women of childbearing age should avoid pregnancy for at least 12–18 months after surgery, as rapid weight loss during this period carries risks for mother and baby. Long-acting reversible contraception (LARC) is recommended, as the absorption of oral contraceptive pills may be unreliable after gastric bypass. Women planning a pregnancy after bariatric surgery should discuss higher-dose folic acid supplementation with their GP or bariatric team.

Urgent red flags: Seek emergency care (call 999 or attend A&E) if you develop severe abdominal or chest pain, breathlessness, a rapid heart rate, high temperature, or swelling and pain in a calf after surgery, as these may indicate a serious complication such as a leak, pulmonary embolism, or deep vein thrombosis. Contact your bariatric team or NHS 111 promptly for persistent vomiting, signs of infection, significant hair loss, or symptoms suggestive of nutritional deficiency such as fatigue, tingling, or low mood.

Not sure if this is normal? Chat with one of our pharmacists →

Aftercare support is provided through the bariatric MDT and typically includes dietetic review, psychological support, and GP monitoring. Support groups — both NHS-facilitated and peer-led — can be invaluable for motivation and practical advice.

Choosing the Right Procedure With Your Surgical Team

Neither NICE nor NHS England recommends one procedure over the other universally; the choice should be made collaboratively with the bariatric MDT based on individual clinical factors, comorbidities, and patient preference.

There is no universally 'better' procedure — the right choice depends on a careful, individualised assessment of clinical factors, personal circumstances, and patient preference. This decision should always be made collaboratively with the bariatric MDT.

Factors that may favour VSG include:

• Preference for a technically simpler operation with a lower risk of internal hernia, marginal ulcers, and dumping syndrome

• Absence of significant type 2 diabetes requiring aggressive metabolic management

• Pre-existing GORD or oesophageal dysmotility (though GORD may worsen after VSG in some patients — discuss with your surgeon)

• Concerns about the complexity of long-term supplementation or medication absorption

Factors that may favour gastric bypass include:

• Significant type 2 diabetes where metabolic remission is a primary goal

• Severe obesity with a higher BMI where greater weight loss is needed

• Willingness and ability to commit to lifelong nutritional monitoring and supplementation

• Absence of factors that increase the risk of marginal ulcers (e.g., active smoking or regular NSAID use that cannot be stopped)

It is important to note that medication absorption may be altered after gastric bypass, including for anticoagulants, oral contraceptives, and other medicines with narrow therapeutic windows. Your surgical and medical team should review all current medications before and after surgery. Patients on anticoagulant therapy require particularly careful monitoring post-operatively.

Other bariatric procedures — such as one-anastomosis gastric bypass (OAGB/MGB) or single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) — may be considered in selected cases, though availability varies by centre. Your MDT will advise on which options are appropriate and available locally.

Neither NICE CG189 nor NHS England commissioning policy recommends one procedure over the other for the general bariatric population; both VSG and RYGB are considered clinically appropriate when performed in accredited centres by experienced surgeons.

Patients are encouraged to ask their surgical team detailed questions about expected outcomes, risks specific to their health profile, and what post-operative support is available. Second opinions are entirely reasonable and supported within NHS practice. Ultimately, the most successful outcomes are achieved when patients are well-informed, psychologically prepared, and supported by a skilled, multidisciplinary team throughout their surgical journey.

Frequently Asked Questions